<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>wegovy Arkiv - NHTA</title>
	<atom:link href="https://nhta.com/tag/wegovy/feed/" rel="self" type="application/rss+xml" />
	<link>https://nhta.com/tag/wegovy/</link>
	<description></description>
	<lastBuildDate>Fri, 22 May 2026 13:23:00 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://nhta.com/wp-content/uploads/2025/06/favicon-150x150.png</url>
	<title>wegovy Arkiv - NHTA</title>
	<link>https://nhta.com/tag/wegovy/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>EMA recommends oral Wegovy for weight management</title>
		<link>https://nhta.com/ema-recommends-oral-wegovy-for-weight-management/</link>
		
		<dc:creator><![CDATA[NHTA]]></dc:creator>
		<pubDate>Fri, 22 May 2026 13:23:00 +0000</pubDate>
				<category><![CDATA[Insights]]></category>
		<category><![CDATA[ema]]></category>
		<category><![CDATA[oral formulation]]></category>
		<category><![CDATA[wegovy]]></category>
		<category><![CDATA[weight management]]></category>
		<guid isPermaLink="false">https://nhta.com/ema-recommends-oral-wegovy-for-weight-management/</guid>

					<description><![CDATA[<p>EMA has recommended an extension to the EU marketing authorisation for Wegovy to add an oral formulation for weight management. Key points Wegovy tablets would be used with diet and physical activity in adults with obesity, or in overweight adults with at least one weight-related comorbidity. The tablets are taken once daily on an empty...</p>
<p>Indlægget <a href="https://nhta.com/ema-recommends-oral-wegovy-for-weight-management/">EMA recommends oral Wegovy for weight management</a> blev først udgivet på <a href="https://nhta.com">NHTA</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>EMA has recommended an extension to the EU marketing authorisation for <strong>Wegovy</strong> to add an oral formulation for weight management.</p>
</p>
<p><strong>Key points</strong></p>
</p>
<ul>
<li>
<p><strong>Wegovy tablets</strong> would be used with diet and physical activity in adults with obesity, or in overweight adults with at least one weight-related comorbidity.</p>
</li>
</ul>
<ul>
<li>
<p>The tablets are taken once daily on an empty stomach, after at least 8 hours of fasting, and users should wait 30 minutes before eating, drinking, or taking other medicines.</p>
</li>
</ul>
<ul>
<li>
<p>This is the first GLP-1 receptor agonist for weight management developed for oral use.</p>
</li>
</ul>
<ul>
<li>
<p>In a phase 3 trial of 307 adults, participants taking Wegovy tablets lost 13.61% of body weight on average, versus 2.18% with placebo.</p>
</li>
</ul>
<ul>
<li>
<p>The most common side effects were gastrointestinal disorders, and the safety profile was similar to weekly Wegovy injections.</p>
</li>
</ul>
<p>The CHMP opinion now goes to the European Commission for a decision. If the extension is granted, price and reimbursement decisions will follow in each Member State.</p>
</p>
<p>Read more at <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ema.europa.eu/en/news/first-oral-glp-1-treatment-weight-management">https://www.ema.europa.eu/en/news/first-oral-glp-1-treatment-weight-management</a></p>
<p>Indlægget <a href="https://nhta.com/ema-recommends-oral-wegovy-for-weight-management/">EMA recommends oral Wegovy for weight management</a> blev først udgivet på <a href="https://nhta.com">NHTA</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
